CY1106853T1 - Χρηση συζευγματων χολικου οξεος ή λιπαρου οξεος χολικου αλατος - Google Patents
Χρηση συζευγματων χολικου οξεος ή λιπαρου οξεος χολικου αλατοςInfo
- Publication number
- CY1106853T1 CY1106853T1 CY20071101160T CY071101160T CY1106853T1 CY 1106853 T1 CY1106853 T1 CY 1106853T1 CY 20071101160 T CY20071101160 T CY 20071101160T CY 071101160 T CY071101160 T CY 071101160T CY 1106853 T1 CY1106853 T1 CY 1106853T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bile acid
- bile
- fatty
- acid
- conjugues
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 5
- 239000003613 bile acid Substances 0.000 title abstract 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 3
- 229930195729 fatty acid Natural products 0.000 abstract 3
- 239000000194 fatty acid Substances 0.000 abstract 3
- 239000003833 bile salt Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL142650A IL142650A (en) | 1998-04-08 | 2001-04-17 | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| PCT/IL2002/000303 WO2002083147A1 (en) | 2001-04-17 | 2002-04-15 | Use of bile acid or bile salt fatty acid conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106853T1 true CY1106853T1 (el) | 2012-05-23 |
Family
ID=11075322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071101160T CY1106853T1 (el) | 2001-04-17 | 2007-09-07 | Χρηση συζευγματων χολικου οξεος ή λιπαρου οξεος χολικου αλατος |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7501403B2 (enExample) |
| EP (2) | EP1790346B1 (enExample) |
| JP (1) | JP4324706B2 (enExample) |
| KR (1) | KR100883080B1 (enExample) |
| CN (1) | CN1259918C (enExample) |
| AT (2) | ATE432705T1 (enExample) |
| AU (2) | AU2002307771B2 (enExample) |
| BR (1) | BR0208924A (enExample) |
| CA (2) | CA2703688C (enExample) |
| CY (1) | CY1106853T1 (enExample) |
| CZ (2) | CZ309042B6 (enExample) |
| DE (2) | DE60220775T2 (enExample) |
| DK (2) | DK1379254T3 (enExample) |
| EA (1) | EA007565B1 (enExample) |
| ES (2) | ES2289137T3 (enExample) |
| HU (1) | HU230548B1 (enExample) |
| IL (1) | IL142650A (enExample) |
| MX (1) | MXPA03009553A (enExample) |
| NO (2) | NO333910B1 (enExample) |
| NZ (1) | NZ528868A (enExample) |
| PL (2) | PL205057B1 (enExample) |
| PT (2) | PT1790346E (enExample) |
| UA (1) | UA78699C2 (enExample) |
| WO (1) | WO2002083147A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| TR201901012T4 (tr) * | 2007-07-25 | 2019-02-21 | Univ Graz Medizinische | Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı. |
| US8470885B2 (en) * | 2009-01-12 | 2013-06-25 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| WO2010086864A1 (en) | 2009-02-02 | 2010-08-05 | Galmed International Ltd. | Methods and compositions for treating alzheimer's disease |
| US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| WO2013166176A1 (en) * | 2012-05-01 | 2013-11-07 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and fxr agonists; compositions and method of uses |
| CN103571617A (zh) * | 2012-07-26 | 2014-02-12 | 丰益(上海)生物技术研发中心有限公司 | 改进的动物油脂加工工艺 |
| ES2701077T3 (es) | 2012-11-29 | 2019-02-20 | St Pharm Co Ltd | Conjugado de oligómero de ácido biliar para un nuevo transporte vesicular y uso del mismo |
| IL227890A0 (en) * | 2013-08-08 | 2014-01-30 | Galderm Therapeutics Ltd | Antiaging compounds containing bile acid and fatty acid conjugates |
| WO2016199137A1 (en) * | 2015-06-10 | 2016-12-15 | Galmed Research And Development Ltd. | Low dose compositions of aramchol salts |
| HUE045209T2 (hu) * | 2013-12-04 | 2019-12-30 | Galmed Res & Development Ltd | Aramchol-sók |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| EP3148549A4 (en) * | 2014-06-01 | 2017-11-15 | Galmed Research and Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN116687850A (zh) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3859437A (en) * | 1972-06-02 | 1975-01-07 | Intellectual Property Dev Corp | Reducing cholesterol levels |
| US3856953A (en) * | 1973-05-15 | 1974-12-24 | Intellectual Property Dev Corp | Method of treating fatty liver |
| IT1167479B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido chenodesossicolico |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5278320A (en) * | 1992-09-11 | 1994-01-11 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| DE4432708A1 (de) * | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| KR20010031501A (ko) * | 1997-10-31 | 2001-04-16 | 추후제출 | 5-알파 환원효소 활성을 조절하는 방법 및 조성물 |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| IL142650A (en) * | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドｘ受容体活性化剤 |
-
2001
- 2001-04-17 IL IL142650A patent/IL142650A/en active IP Right Grant
-
2002
- 2002-04-15 DK DK02761957T patent/DK1379254T3/da active
- 2002-04-15 DK DK07002485T patent/DK1790346T3/da active
- 2002-04-15 AT AT07002485T patent/ATE432705T1/de not_active IP Right Cessation
- 2002-04-15 EP EP07002485A patent/EP1790346B1/en not_active Expired - Lifetime
- 2002-04-15 AU AU2002307771A patent/AU2002307771B2/en not_active Expired
- 2002-04-15 CZ CZ2008296A patent/CZ309042B6/cs not_active IP Right Cessation
- 2002-04-15 PT PT07002485T patent/PT1790346E/pt unknown
- 2002-04-15 EA EA200301017A patent/EA007565B1/ru not_active IP Right Cessation
- 2002-04-15 ES ES02761957T patent/ES2289137T3/es not_active Expired - Lifetime
- 2002-04-15 MX MXPA03009553A patent/MXPA03009553A/es active IP Right Grant
- 2002-04-15 DE DE60220775T patent/DE60220775T2/de not_active Expired - Lifetime
- 2002-04-15 CA CA2703688A patent/CA2703688C/en not_active Expired - Lifetime
- 2002-04-15 PL PL366585A patent/PL205057B1/pl unknown
- 2002-04-15 CA CA2444266A patent/CA2444266C/en not_active Expired - Lifetime
- 2002-04-15 HU HU0400801A patent/HU230548B1/hu unknown
- 2002-04-15 PT PT02761957T patent/PT1379254E/pt unknown
- 2002-04-15 PL PL387458A patent/PL211438B1/pl unknown
- 2002-04-15 WO PCT/IL2002/000303 patent/WO2002083147A1/en not_active Ceased
- 2002-04-15 AT AT02761957T patent/ATE365044T1/de active
- 2002-04-15 CZ CZ20032710A patent/CZ300489B6/cs not_active IP Right Cessation
- 2002-04-15 ES ES07002485T patent/ES2328966T3/es not_active Expired - Lifetime
- 2002-04-15 CN CNB028081870A patent/CN1259918C/zh not_active Expired - Lifetime
- 2002-04-15 US US10/474,032 patent/US7501403B2/en not_active Expired - Lifetime
- 2002-04-15 UA UA2003109404A patent/UA78699C2/uk unknown
- 2002-04-15 BR BR0208924-6A patent/BR0208924A/pt not_active Application Discontinuation
- 2002-04-15 JP JP2002580951A patent/JP4324706B2/ja not_active Expired - Lifetime
- 2002-04-15 KR KR1020037013339A patent/KR100883080B1/ko not_active Expired - Lifetime
- 2002-04-15 NZ NZ528868A patent/NZ528868A/en not_active IP Right Cessation
- 2002-04-15 DE DE60232559T patent/DE60232559D1/de not_active Expired - Lifetime
- 2002-04-15 EP EP02761957A patent/EP1379254B1/en not_active Expired - Lifetime
-
2003
- 2003-10-15 NO NO20034609A patent/NO333910B1/no not_active IP Right Cessation
-
2007
- 2007-01-19 AU AU2007200191A patent/AU2007200191B2/en not_active Expired
- 2007-09-07 CY CY20071101160T patent/CY1106853T1/el unknown
-
2009
- 2009-01-28 US US12/361,291 patent/US8110564B2/en not_active Expired - Lifetime
-
2013
- 2013-09-10 NO NO20131219A patent/NO335087B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106853T1 (el) | Χρηση συζευγματων χολικου οξεος ή λιπαρου οξεος χολικου αλατος | |
| PT1041072E (pt) | Acidos dioxociclopentil hidroxamicos | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| DK1196444T3 (da) | Exendin-4-konjugater og deres medicinske anvendelighed | |
| BR0112104A (pt) | Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel | |
| DE69902647D1 (de) | Fettsäurederivate von gallensäure und gallensäurederivaten | |
| BR0010750A (pt) | Peptìdeos insulinotrópicos de longa duração | |
| CY1112962T1 (el) | 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων | |
| BR9914044A (pt) | ésteres tetrahidropirido | |
| ATE253063T1 (de) | 5-ht1f-agonisten | |
| CY1108770T1 (el) | Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων | |
| CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
| CY1113257T1 (el) | Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων | |
| CY1105047T1 (el) | Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν | |
| CY1105803T1 (el) | Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου | |
| UY27018A1 (es) | Derivados de la pirimidina | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| DE69921486D1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
| BR0115618A (pt) | Derivados de indol e diidroindol | |
| CY1105308T1 (el) | Θepαπεια για υπep-ουρικαιμια | |
| DE60235085D1 (de) | Herstellungsverfahren von derivate von bisphosphonaten |